ReviewAntioxidants (Basel, Switzerland)2025
Redox Control in Platelet Activity and Therapy.
Review in Antioxidants (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- PSG6: A mitochondrially-targeted gentisic acid derivative exerts antiplatelet action via mitochondrial complex I inhibition.Redox biology · 2026Article
- Modulation of Stress and Anabolic Signalling Pathways by Whey Protein Isolate in C2C12 Cells Under Exercise-Mimetic Conditions.Biomedicines · 2026Article
- Succinylation modification in diabetes and diabetic complications: Mechanisms and functions (Review).Molecular medicine reports · 2026Review
- Review
- Redox Regulation of Megakaryocyte Differentiation and Platelet Biogenesis.Antioxidants (Basel, Switzerland) · 2026Review
- Platelet mitochondria dysfunction in diabetes mellitus: mechanisms and therapeutic implications.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Maintaining redox balance is essential for platelet physiology and overall cellular homeostasis. Upon activation, platelets generate reactive oxygen species (ROS), which act as signaling mediators in responses to collagen and are required for collagen-dependent thrombus formation. Multiple enzymatic systems contribute to platelet ROS production, with nicotinamide adenine dinucleotide (phosphate) oxidases (NOX isoforms) serving as the primary source, complemented by cyclooxygenase (COX), xanthine oxidase (XO), and the mitochondrial respiratory chain. Both oxidative and reductive stress disrupt this equilibrium and have been implicated in the pathophysiology of diverse diseases, including bleeding disorders, thrombosis, cardiovascular disorders, diabetes and cancer. In transfusion medicine, mitochondrial dysfunction and the resulting oxidative stress are key drivers of platelet lesion resulting in clearance defects and the progressive loss of hemostatic activity during storage. Targeting platelet-specific redox regulatory pathways represents a promising strategy to better define platelet contributions to human health and to develop interventions that may alter disease outcomes in which platelets play a central role.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.